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Allogeneic hematopoietic stem cell transplantation is the only
curative therapy. Many patients do not have a suitable donor.
Between 1995 – 2006, 25 pediatric patients lacking matched
living stem cell donors were transplanted with unrelated umbil-
ical cord blood (UCB). M:F ratio of the study group was 1.8;
Eight (32%) patients belonged to ethnic minorities; the median
age was 9.77 years (range 1.11-19.73) and median weight was
32.8 kg (range 8.3-62.6). Five patients had therapy-related MDS
(3 ALL, 1 NHL, 1 Neuroblastoma). MDS stage was RA/RC 10
pts, RAEB 7 pts, RAEB-T 3pts, and AML 5 pts. Monosomy 7
was present in 17 (68%) pts. Median time from diagnosis to
transplant was 7.17 months (range 2-61). Preparative regimen
was TBI based in 17 pts (68%). Cyclosporine was used for
GVHD prophylaxis with Solu-medrol in 24 pts and CellCept in
1 pt. Grafts were matched at HLA Class I (A and B) at low
resolution and HLA Class II (DRB1) at the allelic level. 6 pts
were 5/6, 18 pts were 4/6, and 1 pt was 3/6 HLA matched. The
grafts contained a median of 4.39  10e7 (range 1.68-29.16)
nucleated cells/kg pre-cryopreservation and 3.58  10e7/kg
(range 1.01-21.25) infused. The median CD 34 cell dose
infused was 1.5  10e5/kg (range 0.17-28.46). Cumulative in-
cidence of neutrophil engraftment (ANC  500/ L) at day 100,
platelet engraftment (50K untransfused) at day 180, acute
GVHD grades 2-4 at day 100, chronic GVHD, relapse and non
relapse mortality at 1 yr were 72%, 56%, 20%, 32%, 8% and
36.5% respectively. 5 yr probabilities of OS and EFS were 46%
and 41%. Thirteen patients died, 5 of infectious complications
(1 toxoplasmosis, 1 aspergillosis, 2 EBV including 1 LPD, 1
adenovirus), 4 of relapse, 1 of graft failure, and 3 of multi system
organ failure. EFS of pts  10 yrs of age (p  0.05) , weighing
 33kg (p  0.03), and those with monosomy 7 (p  0.05) was
superior. These results, especially in younger patients with
Monosomy 7 and early stage MDS are equivalent to matched
allogeneic bone marrow transplant data. We conclude that un-
related UCB donors should be actively considered for pediatric
patients with MDS who lack a living related or unrelated stem
cell donor to enable transplantation when the disease is in early
stage.
Event Free Survival by Covariates
N Events
1 yr estimate
%(95% CI)
3 yr estimate
(95% CI) p-value
KARYOTYPE 0.05
Monosomy 7
present
17 8 64.7 (42-87.4) 58.8 (35.4-82.2)
Monosomy 7
absent
8 6 37.5 (4-71) 18.8 (0-49.7)
RECIPIENT AGE 0.05
> 10 years 11 9 45.5 (16-74.9) 27.3 (1.0-53.6)
< 10 years 14 5 64.3 (39.2-89.4) 64.3 (39.2-89.4)
RECIPIENT WT. 0.03
> 33 kg 12 10 41.7 (13.8-69.6) 25 (0.5-49.5)
< 33 kg 13 4 69.2 (44.1-94.3) 69.2 (44.1-94.3)
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Primary therapy of high-risk lymphomas in children and ad-
olescents is very successful, however refractory lymphoma pre-
sents major challenges and optimal therapy remains uncertain.
Between 1994 and 2006, 22 pediatric patients with high-risk
lymphoma underwent myeloablative therapy and HSCT; 16
autologous and 7 allogeneic (5 sibling; 2 unrelated HSCT). The
overall EFS was 61% with a median follow up in survivors of
1243 days after HSCT. In 8 Hodgkin’s patients the overall EFS
was 54%; all patients had failed primary therapy, received au-
tologous PBPC and engrafted and one had a planned non-
myeloablative sibling allogeneic HSCT. Relapse occurred in 3
of 4 patients not in CR at 181, 248 and 812 days from HSCT.
In contrast, the 4 of the 5 relapse-free survivors (median follow
up of 833 days; range 305 to 2127) had attained a CR2. The 14
NHL patients’ diagnoses included 6 anaplastic large cell lym-
phomas, 2 peripheral T lymphomas and 6 lymphoblastic lym-
phomas (4 T and 2 B precursor phenotype). Allogeneic HSCT
were performed in 7 NHL patients (5 MS; 2 URD), while 8
patients received autologous PBPC (one autologous patient
relapsed at day 60, then received an allograft). All relapses
occurred before day 100 and 4/5 relapses were in patients who
either had CNS relapses and/or had residual disease at the time
of HSCT. The EFS for all NHL patients was 67% with a
median follow up in survivors of 1756 days (range 224 to 3606
days). In autologous HSCT recipients, the EFS was 50% (me-
dian follow up in survivors was 1071 days; range 224 to 2527),
while after allogeneic HSCT for NHL, the EFS was 83%
(median follow up in survivors was 2283 days; range 496 to
3606). There were no toxic deaths in any patient group. GVHD
occurred in 3/7 allogeneic HSCT patients and resolved with
therapy in all patients. Opportunistic infections typical for al-
logeneic HSCT (speciﬁcally aspergillus, CMV and RSV) oc-
curred more often in the lymphoma patients undergoing autol-
ogous PBPC HSCT compared to pediatric autologous HSCT in
patients with solid tumors. We conclude that myeloablative
HSCT offers signiﬁcant salvage potential in patients with lym-
phoma who have disease refractory to primary therapy. Those
patients who attain disease control prior to HSCT do very well.
We prefer to use TBI-based myeloablation and perform alloge-
neic HSCT in pediatric NHL patients to overcome potential
chemotherapy resistance, decrease the potential of re-infused
tumor and to potentially elicit a GVL effect.
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REDUCED INTENSITY CONDITIONING (RIC) AND HEMATOPOIETIC
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(ECP), FLUDARABINE, AND TARGETED SINGLE DOSE BUSULFAN AS AN
OUTPATIENT PROCEDURE IN CHILDREN: PRELIMINARY RESULTS
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ECP is an immunomodulatory therapy for immune-mediated
disorders, including GVHD. We hypothesize that combining
ECP with RIC prior to and following HSCT will reduce inci-
dence of GVHD and 100-day transplant related mortality
(TRM) without affecting time to engraftment. Ten children
have been enrolled with a mean age of 14 years (10 – 17), with
CML (n2), severe aplastic anemia (SAA) (n4), ALL in CR2
(n1), peripheral T-cell lymphoma (n1), and relapsed
Hodgkin’s after autologous transplant (n2). Stem cell sources
included peripheral blood from matched related (n6), mis-
matched related (n1), and matched unrelated (n3) donors.
Conditioning included 2 weekly treatments of ECP (treat-
ment2 consecutive days) beginning two weeks prior to trans-
plant, ﬂudarabine 30mg/m2/d (days -6 to -2) and targeted dose
busulfan to reach a daily AUC of 4000 mol*min (days -5, -4);
GVHD prophylaxis was: MMF, CSA, and weekly ECP once
total chimerism reached 50% through day 100. Median fol-
low-up is 100 days (33 – 446). Full engraftment (95% total
donor chimerism) was achieved by a median of 29 days (12 – 81)
in 9/10 patients. Two required immune modulation for falling
chimerism; 1 responded to removal of immune suppression, 1
required donor lymphocyte infusion. Major complications were
infectious: central line infections (n5, with 1 episode of hypo-
tension), adenovirus antigenemia (n1), and CMV reactivation
(n5/5 at risk); they underwent pre-emptive treatment without
development of disease. There was 1 TRM: a patient with
heavily treated SAA died of fungal infection after no engraft-
ment. Acute GVHD only occurred in those undergoing immune
modulation (2/10, grade 3). Of 8 evaluable, 2 developed exten-
sive cGVHD; 1 limited. There were no episodes of veno-
occlusive disease or mucositis; none required parenteral nutri-
tion. Patients were admitted to the hospital for 2 days during the
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